Current and future landscape of NASH
Diagnostic algoritm for NAFLD and NASH in clinical practice
Therapy of NAFLD 1: An overview of nonpharmacological modalities
Therapy of NAFLD 2: Pharmacotherapy - metabolic role of UDCA and other bile acids
Diabesity, and cardiovascular risk: How to manage them in patients with NAFLD - an approach for everyday practice
Effect of metabolic and bariatric surgery in patients with NAFLD/NASH
Effect of bariatric surgery in patients with T2DM
Methodology showing different effects of individual techniques
Targeting the gastrointestinal tract in the treatment of obesity/type 2 diabetes and Q of place for bile acids
Gut microbiome and cholestatic liver diseases
Fecal microbiota transplantation as a novel treatment of digestive diseases
Microbiome dysbiosis and hepatocellular carcinoma
SIBO and other gastrointestinal diseases: What is the connection
GERD: Beyond the acid
The risks and benefits of long-term use of proton pump inhibitors
Gastrointestinal motility disorders in Type 2 Diabetes Mellitus
Obesity and gastroesofageal reflux disease
Why the Non-standard approaches to H. pylori eradication are needed?
Intestinal fibrosis in IBD. Do we have a chance to solve it?
Prevention of acute pancreatitis
Cholestasis and IBD in pregnancy
Predictive factors for the effectiveness of primary biliary cholangitis treatment
Alcoholic hepatitis - an update
Дата: 24-26/5/2018
Место: Братислава, Словакия
Участники: 293
